

February 25th 2024

Benedetta Terziroli Beretta-Piccoli
Epatocentro Ticino
CH-6900 Lugano
Switzerland

CURRICULUM VITAE AND BIBLIOGRAPHY

1. PERSONAL INFORMATION

Last name:	Terziroli Beretta-Piccoli
First name:	Benedetta
Birthday:	September 20, 1975, Lugano (Switzerland)
Citizenship:	Swiss
Family status:	Married, 6 children
Business address:	Epatocentro Ticino SA Via Soldino 9 CH - 6900 Lugano Switzerland
Office phone number	+41-91-910 65 70
E-mail:	benedetta.terziroli@hin.ch benedetta.terziroli@usi.ch
Languages:	Italian, German, English, French
Research affiliations:	Institute of Liver Studies, MowatLabs, King's College Hospital, London, UK Institute for Research in Biomedicine, Bel- linzona, Switzerland

2. QUALIFICATIONS

- 2000: Diploma of physician (Swiss Confederation), Award for the best graduation
- 2000: M.D. Thesis (University of Bern, Switzerland)
- 2007: Certification as Internal Medicine Specialist

- 2015: GCP Module 1 and 2, CTU EOC Bellinzona Switzerland
- 2016 : GCP Sponsor-Investigator, CTU EOC Bellinzona Switzerland
- 2022: GCP refresher, Departement Klinische Forschung, Universitäts-
spital Basel
- 2019: Teach the Teacher Course, USI
- 2020: Venia Legendi (Privat Dozent) at the Faculty of Biomedicine,
Università della Svizzera Italiana, Lugano, Switzerland
- 2022: Teaching in the Clinic Course, USI

3. POSTGRADUATE EDUCATION

• INTERNSHIP – RESIDENCY

- 2001-2002: Departement of Internal medicine, Ospedale La Carità,
Locarno, Switzerland
- 2003: Department of Neurology, Ospedale Civico, Lugano, Switzerland
- 2004: Division of Infectious diseases, Ospedale Civico, Lugano,
Switzerland
- 2005: Division of Palliative care, Ospedale Regionale di Bellinzona,
Switzerland
- 2006: Department of Internal Medicine, Ospedale Regionale Lugano,
Switzerland

• CONSULTANT AND PROFESSIONAL POSITIONS

- 2008-2013: Consultant, Ambulatorio Epatologia, Clinica Luganese,
Lugano, Switzerland
- since 2013: Consultant, Epatocentro Ticino, Lugano, Switzerland AND
Consultant physician in hepatology Ospedale La Carità EOC, Locarno,
Switzerland
- since 2020: visiting scientist at Institute for Research in Biomed-
icine, Bellinzona, Switerland

4. RESEARCH

• TRAINING – FELLOWSHIP

- 2006-2008: Hospice Ticino, Switzerland
- since 2013: Epatocentro Ticino, Lugano, Switzerland

Local Principal Investigator for:

- o Identification of common and uncommon gene variations in Primary
Biliary Cirrhosis – genPBC study

- o A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (Native)
- o A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis (Regenerate)
- o A randomized, patient and investigator blinded, placebo-controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatohepatitis (CLMB763X2201)
- o A two-part randomized, double-blind, placebo-controlled multicentre dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (Amber)
- o A phase II, multicentre, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis (Orion)
- o A double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis (NUC-5 Dr. Falk study)
- o Autoimmune idiopathic disorders in HCV patients: effects of direct antiviral agents (DAA) - SASL 42
- o A Phase 3, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis (Primis)
- o A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid (GENFIT)
- o A 24-week, Randomized, Placebo controlled, Double blind, Phase 2b trial of Stetanaxib in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness (TRANSFORM)
- o A Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patients with an inadequate response to ursodeoxycholic acid (NUT-2 PBC)

- o A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (GLISTEN)

Investigator initiated trials (Main Investigator):

- Swiss Association for the Study of the Liver study 36: The health burden of primary biliary cholangitis in Switzerland (<https://sas1.unibas.ch/7studies.php>)
- Swiss Association for the Study of the Liver study 38: Swiss registry on autoimmune hepatitis (<https://sas1.unibas.ch/7studies.php>)
- Swiss Association for the Study of the Liver study 39: Swiss registry on primary biliary cholangitis (<https://sas1.unibas.ch/7studies.php>)
- Liver autoantibodies in patients with chronic hepatitis C infection treated by direct acting antiviral agents. Swiss Hepatitis C cohort Study nested project.
- Autoimmune liver disease serology in acute hepatitis E virus infection.
- 1.1-30-9.2020: research fellow at Institute for Research in Biomedicine, Bellinzona, Switzerland (Federica Sallusto): Autoreactive T cells targeting SEPSECS in type 1 and type 2 autoimmune hepatitis and autoimmune sclerosing cholangitis.
- Liver histology in patients with isolated Primary Biliary Cholangitis-specific serology
- Definition of the autoantibody profile in the Swiss autoimmune liver disease cohorts
- Anti-nuclear antibody antigenic targets in type 1 autoimmune hepatitis
- Effect of anti-COVID-19 mRNA vaccines on development or worsening of autoimmune reactivity in patients with autoimmune liver disease
- Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis (ERN RARE LIVER)
- Histological and serological characterization of acute liver injury after Covid-19 vaccines

International research collaboration:

In 2014 I established a collaboration with the Institute of Liver Studies at King's College Hospital, London, United Kingdom, in particular with Professors Giordina Mieli-Vergani and Diego Vergani, MowatLabs, world authorities in the field of autoimmune liver disease. This collaboration, which has been steadily growing over the years, has proven particularly fruitful, giving me the opportunity to initiate and see to completion research projects, create international links and apply successfully for the establishment of Swiss Autoimmune Liver Disease Registries. The rising interest in liver autoimmunity in our Country has enabled me to organize highly successful international and national scientific meetings. For two of these meetings, owing to their cutting-edge scientific level, I have been invited to collect and publish the meeting contents as guest editor of a prestigious Journal (Journal of Autoimmunity). I received an official affiliation at the Institute of Liver Studies, MowatLabs, King's College Hospital, London, UK in May 2019 by Professor Anil Dhawan. In 2023, I was elected as a member of the steering committee of the International AIH Group (www.iaihg.org), which is a scientific organization providing a platform for carrying out project-based collaborations on AIH and AIH-related diseases. The IAIHG group has issued the AIH diagnostic scoring systems, and continues to publish reference papers in the field.

5. GRANTS

- Grant for Swiss Primary Biliary Cholangitis, Intercept (CHF 50'166)
- Grant for the Swiss Primary Biliary Cholangitis Registry, Intercept (CHF 165'900)
- Grant for the Swiss Autoimmune Hepatitis Registry, Vifor (CHF 20'000)
- Grant for "Liver autoantibodies in patients with chronic hepatitis C infection treated by direct acting antiviral agents", Gilead (CHF 22'800)
- Grant for "Autoreactive T cells targeting SEPSECS in type 1 and type 2 autoimmune hepatitis and autoimmune sclerosing cholangitis", Fondazione Leonardo (CHF 87'000)
 - Renewal of grant for "Autoreactive T cells targeting SEPSECS in type 1 and type 2 autoimmune hepatitis and autoimmune sclerosing cholangitis", Fondazione Leonardo (CHF 34'000)

Grant for the Swiss AIH Cohort Study, dr. Falk (CHF 5'000)

6. SOCIETY MEMBERSHIP

- Swiss Medical Association (FMH)
- European Association for the Study of the Liver, EASL
- American Association for the Study of the Liver, AASLD
- Swiss Association for the Study of the Liver, SASL
- Swiss Society for Allergology and Immunology, SSAI
- International Autoimmune Hepatitis Group, IAIHG, Member of the Steering Committee (since 2023)
- International Primary Sclerosing Cholangitis Study Group, IPSCSG
- Board member and co-founder of SwissHePa
- Swiss Society for Ultrasound in Medicine, SGUM
- Steering Committee of the International Autoimmune Hepatitis Group

7. TEACHING ACTIVITY – MASTER’S THESIS AND MEDICAL DOCTORAL THESIS SUPERVISION

UNDERGRADUATE MEDICAL STUDENT

- Corso elettivo malattie autoimmune di fegato - Università di Milano Bicocca, Italy, January 2017
- Corso elettivo malattie autoimmune di fegato - Università di Milano Bicocca, Italy, 29 May 2018
- Corso di preparazione agli esami federali 2018 dell’Associazione Studenti Ticinesi di Medicina, Switzerland, 11 June 2018
- Master thesis co-director (director: Prof. Mario Bianchetti) at Università della Svizzera Italiana, Switzerland. Title: Post-Extrarenal Immune-Mediated Disorders Linked with Acute Poststreptococcal Glomerulonephritis: a Systematic Review. Clinical Reviews in Allergy & Immunology, doi.org/10.1007/s12016-019-08761-w
- Master thesis director at Università della Svizzera Italiana, Switzerland. Titles:
 - Histological and serological characterization of acute liver injury after Covid-19 vaccines (Greta Codoni)
 - Epidemiology, clinical features and management of autoimmune hepatitis in Switzerland: a retrospective and prospective cohort study (Christine Ludz)
 - Liver autoantibodies before and after SARS-CoV-2 mRNA vaccines in patients with autoimmune liver diseases (Tobias Kälin, ongoing)

POSTGRADUATE MEDICAL STUDENT

- CONTINUAL MEDICAL EDUCATION: Responsible for the postgraduate educational program at Epatocentro Ticino 2013-2022
- SASL School of Hepatology, Primary Biliary Cholangitis, June 13. 2016
- SASL Postgraduate course, Ermatingen, Switzerland November 12. 2017
- SASL Postgraduate course, Vevey, Switzerland November 21. 2019
- PhD Thesis Examineur, Université Grenoble Alpes, France, 27.3.2019
- SASL Postgraduate course, Ermatingen, Switzerland November 17. 2023

- Scientific meeting organization:
 - Simposio Ticinese di Epatologia 2013 - 2014 - 2015 - 2016 - 2017 - 2018 - 2019
 - 1st Swiss Autoimmune Liver Disease Meeting, Lugano, May 20, 2016
 - 2nd Swiss Autoimmune Liver Disease Meeting, Lugano, April 20, 2018
 - Ian Mackay Meeting, Lugano, September 23th-25th, 2018
 - 3rd Swiss Autoimmune Liver Disease Meeting, Lugano, March 13th-14th 2020
 - 4th Swiss Autoimmune Liver Disease Meeting, Lugano, September 21st-22nd 2023

Doctoral thesis director:

- Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity? (Michele Ghielmetti)
- Acute liver injury with autoimmune features following SARS-CoV-2 vaccination in an ERN/IAIHG cohort: autoimmune hepatitis versus drug-induced autoimmune-like hepatitis (Donald Malino, ongoing, presented at the 4th Swiss Autoimmune Liver Disease Meeting, Lugano, September 22nd 2023)

8. ACTIVITY AS REVIEWER (with IF only)

Journal of Hepatology [Impact factor 25.7]
Hepatology [Impact factor 13.5]
Emerging Microbes and Infections [Impact factor 13.2]
Journal of Autoimmunity [Impact factor 12.8]
Clinical Gastroenterology and Hepatology [Impact factor 12.6]
eBioMedicine [Impact factor 11.1]
American Journal of Gastroenterology [Impact factor 9.8]
Npj vaccines [Impact factor 9.2]
International Journal of infectious diseases [Impact factor 8.4]
Journal of Hepatology Reports [Impact factor 8.3]
European Journal of Internal Medicine [Impact factor 8]
Alimentary Pharmacology & Therapeutics [Impact factor 7.6]
Frontiers in immunology [Impact factor 7.3]
Clinical Chemistry and Laboratory Medicine [Impact factor 6.8]
Liver International [Impact factor 6.7]
United European Gastroenterology Journal [Impact factor 6]
Journal of Paediatrics [Impact factor 5.1]
Therapeutic Advances in Medical Oncology [Impact factor 4.9]
Viruses [Impact factor 4.7]
Liver transplantation [Impact factor 4.6]
Scientific reports [Impact factor 4.6]
Digestive and Liver Diseases [Impact factor 4.5]
Microorganisms [Impact factor 4.5]
Immunologic research [Impact factor 4.4]
Annals of medicine [Impact factor 4.4]
Therapeutic Advances in Gastroenterology [Impact factor 4.2]
Journal of Gastroenterology and Hepatology [Impact factor 4.1]
Heliyon [Impact factor 4]
Journal of Clinical Medicine [Impact factor 3.9]
Pediatric obesity [Impact factor 3.8]
PlosOne [Impact factor 3.7]
European Journal of Paediatrics [Impact factor 3.6]
Therapeutic Advances in Chronic Disease [Impact factor 3.5]

Expert Opinion on Pharmacotherapy [Impact factor 3.2]
Digestive Diseases and Sciences [Impact factor 3.1]
BMJ Open Gastroenterology [Impact factor 3.1]
Journal of Pediatric Gastroenterology and Nutrition [Impact factor 2.9]
BMJ open [Impact factor 2.9]
European Journal of Gastroenterology & Hepatology [Impact factor 2.1]
Scandinavian Journal of Gastroenterology [Impact factor 1.9]
Arab Journal of Gastroenterology [Impact factor 1.4]
Journal of Oncology [Impact factor 1.3]

9. EDITORIAL BOARDS

- Clinical Reviews in Allergy and Immunology: editorial board member
- Clinical Reviews in Allergy and Immunology: guest editor, two special issues 2017
- Journal of Translational Autoimmunity: editorial board member (2018-2023)
- Journal of Autoimmunity: member of the Editorial Board
- Journal of Autoimmunity: guest editor, special issue 2018

10. BIBLIOGRAPHY (EXCLUSIVELY PEER-REVIEWED JOURNALS WITH IMPACT FACTOR)

Due to my marriage, my surname has been reported differently in the literature. In order to facilitate the reading of the present document, my surname is here consistently reported as "Terziroli Beretta-Piccoli".

Hirsch-index: 26 ("Scopus", January 10th 2024)

- Original papers (including systematic reviews)

1. Stoffel PB, Sauvain MJ, von Vigier RO, **Terziroli Beretta-Piccoli BC**, Ramelli GP, Bianchetti MG: Noninfectious causes of uveitis in 70 Swiss children. *Acta Paediatr* 2000; 89: 955-958. [[Impact factor 3.8; Maximum ranking 0.873](#)]
2. **Terziroli Beretta-Piccoli BC**, Sauvain MJ, Gal I, Schibler A, Saurmann T, Kressebuch H, Bianchetti MG: Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature. *Eur J Pediatr* 2000; 159: 594-601. [[Impact factor 3.6; Maximum ranking 0.812](#)]
3. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, **Terziroli Beretta-Piccoli B**, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT; Swiss HIV Cohort Study. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. *Antivir Ther* 2007; 12: 931-939. [[Impact factor 1.2; Maximum ranking 0.078](#)]
4. Stickel F, Helbling B, Heim M, Geier A, Hirschi C, **Terziroli Beretta-Piccoli B**, Wehr K, De Gottardi A, Negro F, Gerlach T. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. *J Viral Hepat* 2012;19:77-87. DOI: 10.1111/j.1365-2893.2011.01527.x. [[Impact factor 2.5; Maximum ranking 0.236](#)]
5. **Terziroli Beretta-Piccoli B**, Guillod C, Marsteller I, Blum R, Mazzucchelli L, Mondino C, Invernizzi P, Gershwin ME, Mainetti C. Primary biliary cholangitis associated with skin disorders: A case report and review of the literature. *Arch Immunol Ther Exp (Warsz)* 2017; 65: 299-309. DOI: 10.1007/s00005-016-0448-0. [[Impact factor 3.2; Maximum ranking 0.320](#)]
6. Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, **Terziroli Beretta-Piccoli B**, van Hoek B, Vierling JM, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG). Expert clinical management of autoimmune hepatitis in the real world. *Aliment Pharmacol Ther* 2017; 45: 723-732. DOI: 10.1111/apt.13907. [[Impact factor 7.6; Maximum ranking 0.930](#)]
7. Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, Braun D, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, **Terziroli Beretta-Piccoli B**, Mertens JC. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. *Liver Int* 2017; 37: 369-376. [[Impact factor 6.7; Maximum ranking 0.790](#)]

8. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. *World J Gastroenterol* 2017;23: 6030-6048. [[Impact factor 4.3](#); [Maximum ranking 0.651](#)]
9. De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, **Terziroli Beretta-Piccoli B**, Magenta L, Semela D, Buscarini E, Langlet P, Görtzen J, Puente A, Müllhaupt B, Navascuès C, Nery F, Deltenre P, Turon F, Engelmann C, Arya R, Caca K, Peck-Radosavljevic M, Leebeek FWG, Valla D, Garcia-Pagan JC; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. *Liver Int* 2017; 37: 694-699. DOI: 10.1111/liv.13285. [[Impact factor 6.7](#); [Maximum ranking 0.790](#)]
10. Fraga M, Doerig C, Moulin H, Bihl F, Brunner F, Müllhaupt B, Ripellino P, Semela D, Stickel F, **Terziroli Beretta-Piccoli B**, Aubert V, Telenti A, Greub G, Sahli R, Moradpour D. Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland. *Liver Int*. DOI: 10.1111/liv.13557. [[Impact factor 6.7](#); [Maximum ranking 0.790](#)]
11. **Terziroli Beretta-Piccoli B**, Invernizzi P, Gershwin ME, Mainetti C. Skin manifestations associated with autoimmune liver diseases: a systematic review. *Clin Rev Allergy Immunol* 2017; 53: 394-412. DOI 10.1007/s12016-017-8649-9. [[Impact factor 9.1](#); [Maximum ranking 0.875](#)]
12. **Terziroli Beretta-Piccoli B**, Stirnimann G, Cerny A, Semela D, Hessler R, Helbling B, Stickel F, Khalid-de Bakker C, Bihl F, Giostra E, Filipowicz Sinnreich M, Oneta C, Baserga A, Invernizzi P, Carbone M, Mertens J. Geoepidemiology of Primary Biliary Cholangitis: lessons from Switzerland. *Clin Rev Allergy Immunol* 2017. DOI 10.1007/s12016-017-8656-x. [[Impact factor 9.1](#); [Maximum ranking 0.875](#)]
13. Keiser O, Giudici F, Müllhaupt B, Junker C, Dufour JF, Moradpour D, Bruggmann P, **Terziroli Beretta-Piccoli B**, Semela D, Brezzi M, Bertisch B, Estill J, Negro F, Spuerri A; Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. *J Viral Hepat* 2018. DOI: 10.1111/jvh.12803. [[Impact factor 2.5](#); [Maximum ranking 0.236](#)]
14. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Bertoli R, Mazzucchelli L, Nofziger C, Paulmichl M, Vergani D. Atovaquone/proguanil-induced autoimmune-like hepatitis. *Hepatol Comm* 2017. DOI: 10.1002/hep4.1039. [[Impact factor 5.1](#); [Maximum ranking 0.726](#)]
15. Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; **European HCV Resistance Study Group** (listed among collaborators: **Ter-**

Terziroli Beretta-Piccoli B). Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-acting Antivirals. *Gastroenterology*. 2017. DOI: 10.1053/j.gastro.2017.11.007. [Impact factor 29.4; Maximum ranking 0.973]

16. Bachofner J, Valli PV, Bergamin I, Kröger A, Künzler P, Baserga A, Braun DL, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, **Terziroli Beretta-Piccoli B**, Mertens J, The Swiss Hepatitis C Cohort Study. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. *Swiss Med Wkly*. 2018 Jan 29;148:w14560. DOI: 10.4414/smw.2018.14560. [Impact factor 2.9; Maximum ranking 0.521]

17. Zenouzi R, Liwinski T, Yamamura J, Weiler-Normann C, Sebode M, Keller S, Lohse AW, Schramm C; International PSC Study Group (IPSCSG) (listed among collaborators: **Terziroli Beretta-Piccoli B**). Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret. *Aliment Pharmacol Ther*. 2018 May 9. DOI: 10.1111/apt.14797. [Impact factor 7.6; Maximum ranking 0.930]

18. **Terziroli Beretta-Piccoli B**, Ripellino P, Gobbi C, Cerny A, Baserga A, Di Bartolomeo C, Bihl F, Deleonardi G, Melidona L, Grondona AG, Mieli-Vergani G, Vergani D, Muratori L, and the *Swiss Autoimmune Hepatitis Cohort Study Group. Autoimmune liver disease serology in acute hepatitis E virus infection. *J Autoimmun* 2018 Nov, 94; 1-6. DOI: 10.1016/j.jaut.2018.07.006. [Impact factor 12.8; Maximum ranking 0.916]

19. **Terziroli Beretta-Piccoli B**, Thompson R, Foskett P, Cerny, Merlo E, Vergani D, Rougemont AL, Moix I, Mieli-Vergani G, Morris M. A novel large heterozygous ABCB4 deletion is associated with severe cholestatic liver disease. *Hepatology*. 2019 May 24. DOI: 10.1002/hep.30783. [Impact factor 13.5; Maximum ranking 0.930]

20. **Terziroli Beretta-Piccoli B**, Di Bartolomeo C, Deleonardi G, AG Grondona, Silvestri, Tesei C, Melidona L, Cerny A, Mertens J, Semmo N, Semela D, Moradpour D, Mieli-Vergani G, Vergani D, Muratori L. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. *J Autoimmun* 2019, Apr 29. pii: S0896-8411(19)30186-6. DOI: 10.1016/j.jaut.2019.04.019. [Impact factor 12.8; Maximum ranking 0.916]

21. Brezzi M †, Bertisch B, Roelens M, Moradpour D, **Terziroli Beretta-Piccoli B**, Semmo N, Müllhaupt B, Semela D, Negro F, Keiser O and the Swiss Hepatitis C Cohort Study. Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.

PlosOne, 2019, 14(6): e0218706. DOI: 10.1371/journal.pone.0218706. [Impact factor 3.7; Maximum ranking 0.651]

22. Efe C, Taşçılar K, Henriksson I, Lytvyak E, Alalkim F, Trivedi H, Eren F, Eliasson J, **Terziroli Beretta-Piccoli B**, Fischer J, Çalışkan AR, Chayanupatkul M, Coppo C, Ytting H, Purnak T, Muratori L, Werner M, Muratori P, Rorsman F, Önnérhag K, Günşar F, Nilsson E, Heurgué-Berlot A, Güzelbulut F, Demir N, Gönen C, Semela D, Aladağ M, Kıyıcı M, Schiano TD, Montano-Loza AJ, Berg T, Ozaslan E, Yoshida EM, Bonder A, Marschall HU, Wahlin S. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis. *Am J Gastroenterol.* 2019 Jun 19. DOI: 10.14309/ajg.0000000000000290. [Impact factor 9.8; Maximum ranking 0.898]

23. Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, Janneke van der Woude C, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Darette LM, Marzioni M, Yimam KK, Perin N, Floreani A, **Terziroli Beretta-Piccoli B**, Rogers JK; International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy C. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol.* 2019 May 14. pii: S1542-3565(19)30523-3. DOI: 10.1016/j.cgh.2019.05.013. [Impact factor 12.6; Maximum ranking 0.919]

24. Bertola E, Simonetti G, Del Giorno R, Giannini O, Fossali, Meoli M, Bianchetti MG, **Terziroli Beretta-Piccoli B**, Milani G. Extrarenal immune-mediated disorders linked with poststreptococcal glomerulonephritis: a systematic review. *Clinical Reviews in Allergy & Immunology*, doi.org/10.1007/s12016-019-08761-w [Impact factor 9.1; Maximum ranking 0.875]

25. Ripellino P, Pasi E, Melli G, Staedler C, Fraga M, Moradpour D, Sahli R, Aubert V, Martinetti Lucchini G, Bihl F, Bernasconi E, **Terziroli Beretta-Piccoli B**, Cerny A, Dalton HR, Zehnder C, Mathis B, Zecca C, Disanto G, Kaelin-Lang A, Gobbi C. Neurological complications of acute hepatitis E virus infection. *Neurol Neuroimmunol Neuroinflamm.* 2019 Dec 5;7(1). pii: e643. doi: 10.1212/NXI.0000000000000643. Print 2020 Jan [Impact factor 8.8; Maximum ranking 0.936]

26. Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knappe W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Glud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal

AJ; **REGENERATE Study Investigators**. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2019 Dec 14; 394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. [[Impact factor 168.9](#); [Maximum ranking 0.997](#)]

After Venia Legendi:

27. Bossen L, Rebora P, Bernuzzi F, Jepsen P, Gerussi A, Andreone P, Galli A, **Terziroli B**, Alvaro D, Labbadia G, Aloise C, Baiocchi L, Giannini E, Abenavoli L, Toniutto P, Marra F, Marzioni M, Niro G, Floreani A, Møller HJ, Valsecchi MG, Carbone M, Grønbaek H, Invernizzi P. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. *Liver Int.* 2020 Jun;40(6):1408-1414. doi: 10.1111/liv.14466. Epub 2020 Apr 24. [[Impact factor 6.7](#); [Maximum ranking 0.790](#)]

28. Efe C, Torgutalp M, Henriksson I, Alalkim F, Lytvyak E, Trivedi H, Eren F, Fischer J, Chayanupatkul M, Coppo C, Purnak T, Muratori L, Werner M, Muratori P, Rorsman F, Onnerhag K, Nilsson E, Heurgué-Berlot A, Demir N, Semela D, Kızılcı M, Schiano TD, Montano-Loza AJ, Berg T, Ozaslan E, Yoshida EM, Bonder A, Marschall H-U, **Terziroli Beretta-Piccoli B**, Wahlin S. Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence, significance for clinical presentation and disease outcome. *J Gastroenterol Hepatol.* 2021 Apr;36(4):936-942. doi: 10.1111/jgh.15214. Epub 2020 Aug 23. [[Impact factor 4.1](#); [Maximum ranking 0.597](#)]

29. Gerussi A, Bernasconi DP, O'Donnell SE, Lammers WJ, Van Buuren H, Hirschfield G, Janssen H, Corpechot C, Reig A, Pares A, Battezzati PM, Zuin MG, Cazzagon N, Floreani A, Nevens F, Gatselis N, Dalekos G, Mayo MJ, Thorburn D, Bruns T, Mason AL, Verhelst X, Kowdley K, van der Meer A, Niro GA, **Beretta-Piccoli BT**, Marzioni M, Belli LS, Marra F, Valsecchi MG, Lindor KD, Invernizzi P, Hansen BE, Carbone M; Italian PBC Study Group and the GLOBAL PBC Study Group. Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. *Clin Gastroenterol Hepatol.* 2021 Aug;19(8):1688-1697.e14. doi: 10.1016/j.cgh.2020.08.006. Epub 2020 Aug 7. [[Impact factor 12.6](#); [Maximum ranking 0.919](#)]

30. **Terziroli Beretta-Piccoli B**, Stirnimann G, Mertens J, Semela D, Zen Y, Mazzucchelli L, Voreck A, Kolbus N, Merlo E, Di Bartolomeo C, Messina P, Cerny A, Costantini S, Vergani D, Mieli-Vergani G; Swiss PBC Cohort Study Group. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines. *J Autoimmun.* 2021 Jan;116:102578. doi: 10.1016/j.jaut.2020.102578. Epub 2020 Nov 20. [[Impact factor 12.8](#); [Maximum ranking 0.916](#)]

31. Avena A, Puggelli S, Morris M, Cerny A, Andrade AR, Pareti E, Bihl F, Cassatella D, Moix I, Merlo E, Rougemont AL, Majno-Hurst P, Vergani D, Mieli-Vergani G, **Terziroli Beretta-Piccoli B**. ABCB4 variants in adult patients with cholestatic disease are frequent and underdiagnosed. *Dig Liver Dis*. 2020 Dec 31:S1590-8658(20)31086-0. doi: 10.1016/j.dld.2020.12.003. Epub ahead of print. [Impact factor 4.5; Maximum ranking 0.683]
32. Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer KH, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C; **European HCV Resistance Study Group** (listed among collaborators: **Terziroli Beretta-Piccoli B**). Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. *Clin Gastroenterol Hepatol*. 2021 Jan;19(1):195-198.e2. doi: 10.1016/j.cgh.2019.10.051. Epub 2019 Nov 6. [Impact factor 12.6; Maximum ranking 0.919]
33. Ghielmetti M, Schaufelberger HD, Mieli-Vergani G, Cerny A, Dayer E, Vergani D, **Terziroli Beretta-Piccoli B**. Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity? *J Autoimmun*. 2021 Jul 15;123:102706. doi: 10.1016/j.jaut.2021.102706. [Impact factor 12.8; Maximum ranking 0.916]
34. Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, et al., for the **NATIVE Study Group**. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. *N Engl J Med* 2021 Oct 21; 385:1547-1558 DOI: 10.1056/NEJMoa2036205. [Impact factor 158.5; Maximum ranking 0.991]
35. Bronz G, Betti C, Rinoldi PO, Kottanattu L, Bianchetti MG, Consolascio D, Bergmann MM, Milani GP, **Terziroli Beretta Piccoli B**, Lava SAG. Infections or Vaccines Associated with Finkelstein-Seidlmayer Vasculitis: Systematic Review. *Clin Rev Allergy Immunol*. 2022 May 12:1-9. doi: 10.1007/s12016-022-08940-2. [Impact factor 9.1; Maximum ranking 0.875]
36. Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Long-term persistence

of HCV resistance-associated substitutions after DAA treatment failure. *J Hepatol.* 2022 Aug 25:S0168-8278(22)03016-1. doi: 10.1016/j.jhep.2022.08.016. [Impact factor 25.7; Maximum ranking 0.962]

37. Clement CC, Osan J, Buque A, Nanaware PP, Chang YC, Perino G, Shetty M, Yamazaki T, Tsai WL, Urbanska AM, Calvo-Calle JM, Ramsamooj S, Ramsamooj S, Vergani D, Mieli-Vergani G, **Terziroli Beretta-Piccoli B**, Gadina M, Montagna C, Goncalves MD, Sallusto F, Galluzzi L, Soni RK, Stern LJ, Santambrogio L. PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes. *Sci Immunol.* 2022 Aug 12;7(74):eabl3795. doi: 10.1126/sciimmunol.abl3795. [Impact factor 24.8; Maximum ranking 0.972]

38. Efe C, Kulkarni AV, **Terziroli Beretta-Piccoli B**, Magro B, Stättermayer A, Cengiz M, Clayton-Chubb D, Lammert C, Bernsmeier C, Gül Ö, la Tijera FH, Anders M, Lytvyak E, Akın M, Purnak T, Liberal R, Peralta M, Ebik B, Duman S, Demir N, Balaban Y, Urzua Á, Contreras F, Venturelli MG, Bilgiç Y, Medina A, Giralda M, Günşar F, Londoño MC, Androutsakos T, Kisch A, Yurci A, Güzelbulut F, Çağın YF, Avcı E, Akyıldız M, Dindar-Demiray EK, Harputluoğlu M, Kumar R, Satapathy SK, Mendizabal M, Silva M, Fagioli S, Roberts SK, Soylu NK, Idilman R, Yoshida EM, Montano-Loza AJ, Dalekos GN, Ridruejo E, Schiano TD, Wahlin S. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. *Hepatology.* 2022 May 14:10.1002/hep.32572. doi: 10.1002/hep.32572.35567545 [Impact factor 13.5; Maximum ranking 0.930]

39. Bronz G, Faré PB, Lava SAG, Bianchetti MG, Simonetti GD, Scoglio M, **Terziroli Beretta-Piccoli B**, Agostoni C, Milani GP. Coronavirus disease 2019, vaccination against coronavirus and immunoglobulin A-mediated diseases: systematic literature review. *J Autoimmun.* 2022 Aug 22;132:102899. doi: 10.1016/j.jaut.2022.102899. [Impact factor 12.8; Maximum ranking 0.916]

40. Pape S, Snijders RJALM, Gevers TJG, Chazouilleres O, Dalekos GN, Hirschfield GM, Lenzi M, Trauner M, Manns MP, Vierling JM, Montano-Loza AJ, Lohse AW, Schramm C, Drenth JPH, Heneghan MA; **International Autoimmune Hepatitis Group (IAIHG) collaborators(†)**. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. *J Hepatol.* 2022 Apr;76(4):841-849. doi: 10.1016/j.jhep.2021.12.041. [Impact factor 25.7; Maximum ranking 0.962]

41. Bergquist A, Weismüller TJ, Levy C, Rupp C, Joshi D, Nayagam JS, Montano-Loza AJ, Lytvyak E, Wunsch E, Milkiewicz P, Zenouzi R, Schramm C, Cazzagon N, Floreani A, Liby IF, Wiestler M, Wedemeyer H, Zhou T, Strassburg CP, Rigopoulou E, Dalekos G, Narasimman M, Verhelst X, Degroote H, Vesterhus M, Kremer AE, Bündgens B, Rorsman F, Nilsson E,

Jørgensen KK, von Seth E, Cornillet Jeannin M, Nyhlin N, Martin H, Kechagias S, Wiencke K, Werner M, **Beretta-Piccoli BT**, Marzioni M, Isoniemi H, Arola J, Wefer A, Söderling J, Färkkilä M, Lenzen H; International PSC Study Group. Impact on follow-up strategies in patients with primary sclerosing cholangitis. *Liver Int.* 2022 May 10. doi: 10.1111/liv.15286. [[Impact factor 6.7; Maximum ranking 0.790](#)]

42. Montano-Loza AJ, Ronca V, Ebadi M, Hansen BE, Hirschfield G, Elwir S, Alsaed M, Milkiewicz P, Janik MK, Marschall HU, Burza MA, Efe C, Çalışkan AR, Harputluoglu M, Kabaçam G, Terrabuio D, de Quadros Onofrio F, Selzner N, Bonder A, Parés A, Llovet L, Akyıldız M, Arikan C, Manns MP, Taubert R, Weber AL, Schiano TD, Haydel B, Czubkowski P, Socha P, Ołdak N, Akamatsu N, Tanaka A, Levy C, Martin EF, Goel A, Sedki M, Jankowska I, Ikegami T, Rodriguez M, Sterneck M, Weiler-Normann C, Schramm C, Donato MF, Lohse A, Andrade RJ, Patwardhan VR, van Hoek B, Biewenga M, Kremer AE, Ueda Y, Deneau M, Pedersen M, Mayo MJ, Floreani A, Burra P, Secchi MF, **Beretta-Piccoli BT**, Sciveres M, Maggiore G, Jafri SM, Debray D, Girard M, Lacaille F, Lytvayak E, Mason AL, Heneghan M, Oo YH; International Autoimmune Hepatitis Group (IAIHG). Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. *J Hepatol.* 2022 Jul;77(1):84-97. doi: 10.1016/j.jhep.2022.01.022. [[Impact factor 25.7; Maximum ranking 0.962](#)]

43. Codoni G, Kirchner T, Engel B, Villami AM, Efe C, Stättermayer AF, Weltzsch JP, Sebode M, Bernsmeier C, Lleo A, Gevers T JG, Kupčinskis L, Castiella A, Pinazo J, De Martin E, Bobis I, Sandah TD, Pedica F, Invernizzi F, Del Poggio P, Bruns T, Kolev M, Semmo N, Bessone F, Giguët B, Poggi G, Ueno M, Jang H, Elpek GO, Soyulu NK, Cerny A, Wedemeyer H, Vergani D, Mieli-Vergani G, Lucena MI, Andrade RJ, Zen Y, Taubert R, **Terziroli Beretta-Piccoli B**. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. *JHEP Rep.* 2022 Oct 13;5(1):100605. doi: 10.1016/j.jhepr.2022.100605. [[Impact factor 8.3; Maximum ranking 0.866](#)]

44. Uzun S, Zinner C, Beenen A, Alborelli I, Bartoszek EM, Yeung J, Calgua de Leon B, Reinscheid M, Bonsert P, Stalder AK, Haslbauer J, Vosbeck J, Mazzucchelli L, Hoffmann T, Terracciano LM, Hutter G, Manz M, Penne I, Bengsch B, Heim MH, Bernsmeier C, Jiang S, Tzankov A, **Terziroli Beretta-Piccoli B** and Matter MS. Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics. *J Hepatol.* 2023 Sep;79(3):666-676. doi: 10.1016/j.jhep.2023.05.020. Epub 2023 Jun 7. [[Impact factor 25.7; Maximum ranking 0.962](#)]

45. Gatselis NK, Zachou K, Loza AJM, Cançado ELR, Arinaga-Hino T, Muratori P, Efe C, Floreani A, Invernizzi P, Takahashi A, Takaki A, **Beretta-Piccoli BT**, van Hoek B, Lytvyak E, Guedes LV, Purnak T, Cazzagon N, Lygoura V, Arvaniti P, Rigopoulou EI, Muratori L, Dalekos GN; International Autoimmune Hepatitis Group. Prevalence and significance of antimitochondrial antibodies in autoimmune hepatitis (AIH): Results from a large multicentre study of the International AIH Group. *Eur J Intern Med*. 2023 Oct;116:43-50. doi: 10.1016/j.ejim.2023.06.001. Epub 2023 Jun 10. [[Impact factor 8; Maximum ranking 0.866](#)]

46. **Terziroli Beretta-Piccoli B**, Buescher G, Dalekos G, Zachou K, Geerts A, Semmo N, Kolev M, De Martin E, Janik MK, Madaleno J, Lalosevic Stojkovic M, Dumortier J, Vanwolleghem T, Schregel I, Steinmann S, Lacaille F, Sebode M. Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis. *J Autoimmun*. 2023 Sep 14;140:103113. doi: 10.1016/j.jaut.2023.103113. [[Impact factor 12.8; Maximum ranking 0.916](#)]

47. Ludz C, Stirnimann G, Semela D, Mertens J, Kremer AE, Filipowicz Sinnreich M, Sokollik C, Bernsmeier C, Bresson-Hadni S, McLin V, Rock N, Braegger C, Posovszky C, Müller P, Cremer M, De Gottardi A, Galante A, Furlano R, Righini-Grunder F, Becker B, Böhm S, Heyland K, Nydegger A, Limoni C, Vergani D, Mieli-Vergani G, Di Bartolomeo C, Cerny A, **Terziroli Beretta-Piccoli B**. Epidemiology, clinical features and management of autoimmune hepatitis in Switzerland: a retrospective and prospective cohort study. *Swiss Med Wkly*. 2023 Aug 31;153:40102. doi: 10.57187/smw.2023.40102. [[Impact factor 2.9; Maximum ranking 0.521](#)]

48. Bronz G, Gianini J, Passi AG, Rizzi M, Bergmann MM, Milani GP, Lava SAG, Bianchetti MG, **Terziroli Beretta-Piccoli B**, Vanoni F. Autoimmune markers and vascular immune deposits in Finkelstein-Seidlmayer vasculitis: Systematic literature review. *J Autoimmun*. 2023 Feb 22;136:103002. doi: 10.1016/j.jaut.2023.103002. [[Impact factor 12.8; Maximum ranking 0.916](#)]

49. Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Gasbarrini A, Dumortier J, Riveiro-Barciela M, Gevers TG, **Terziroli Beretta-Piccoli B**, Londoño MC, Frankova S, Rösner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode S, Schulze K. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver disease. *Front Immunol* 2023

<https://doi.org/10.3389/fimmu.2023.1326078> [Impact factor 7.3; Maximum ranking 0.780]

50. Vismara SA, Ridolfi A, Faré PB, Bianchetti MG, Lava SAG, Renzi S, **Terziroli Beretta-Piccoli B**, Milani GP, Kottanattu L. COVID-19, Coronavirus Vaccines, and Possible Association with Lipschütz Vulvar Ulcer: A Systematic Review. Clin Rev Allergy Immunol. 2023 Oct;65(2):166-171. doi: 10.1007/s12016-023-08961-5. [Impact factor 9.1; Maximum ranking 0.875]

50. Consolascio D, Bronz G, Lardelli PF, Milani GP, Lava SAG, **Terziroli Beretta Piccoli B**, Bianchetti MG, Bergmann MM, Rizzi M. Hoi-gné's syndrome, an uncommon mimicker of anaphylaxis: Systematic literature review. J Autoimmun. 2024 Jan 8;143:103164. doi: 10.1016/j.jaut.2023.103164. [Impact factor 12.8; Maximum ranking 0.916]

• Narrative reviews

1. Pfefferle M, Bihl F, **Terziroli Beretta-Piccoli B**, Cerny A. Betreuung des Patienten mit Leberzirrhose. Ther Umsch 2011; 68: 207-211. [Without Impact factor]

2. **Terziroli Beretta-Piccoli B**, Schranz M, De Gottardi A, Cerny A. Update Hepatitis B und C. Praxis (Bern 1994) 2015; 104: 1393-1397. [Without Impact factor]

3. **Terziroli Beretta-Piccoli B**, Vergani D, Mieli-Vergani G. Autoimmunhepatitis: das Wichtigste für die Praxis. Ther Umsch 2017; 74: 115-121. [Without Impact factor]

4. Mainetti C, **Terziroli Beretta-Piccoli B**, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review. Clin Rev Allergy Immunol 2017. DOI: 10.1007/s12016-017-8652-1. [Impact factor 9.1; Maximum ranking 0.875]

5. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D. Serology in autoimmune hepatitis. A clinical-practice approach. Eur J Intern Med 2017. DOI: 10.1016/j.ejim.2017.10.006. [Impact factor 8; Maximum ranking 0.886]

6. Lerch M, Mainetti C, **Terziroli Beretta-Piccoli B**, Harr T. Current perspectives on Stevens-Johnson Syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol 2018. DOI: 10.1007/s12016-017-8654-z. [Impact factor 10.817; Maximum ranking 0.893]

7. **Terziroli Beretta-Piccoli B**, Mainetti C, Peeters MA, Laffitte E. Cutaneous granulomatosis: a comprehensive review. Clin Rev Allergy Immunol 2018. DOI: 10.1007/s12016-017-8666-8. [Impact factor 9.1; Maximum ranking 0.875]

8. Lerch M, Mainetti C, **Terziroli Beretta-Piccoli B**, Harr T. Current perspectives on Erythema Multiforme. Clin Rev Allergy Immunol 2018. DOI: 10.1007/s12016-017-8667-7. [Impact factor 9.1; Maximum ranking 0.875]
9. **Terziroli Beretta-Piccoli B**, Vergani D, Mieli-Vergani G Autoimmune sclerosing cholangitis: Evidence and open questions. J Autoimmun. 2018 Dec;95:15-25. DOI: 10.1016/j.jaut.2018.10.008. [Impact factor 12.8; Maximum ranking 0.916]
10. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview. J Autoimmun. 2018 Dec;95:144-158. DOI: 10.1016/j.jaut.2018.10.004. [Impact factor 12.8; Maximum ranking 0.916]
11. Sokollik C, McLin VA, Vergani D, **Terziroli Beretta-Piccoli B**, Mieli-Vergani G. Juvenile autoimmune hepatitis: A comprehensive review J Autoimmun. 2018 Dec;95:69-76. DOI: 10.1016/j.jaut.2018.10.007. [Impact factor 12.8; Maximum ranking 0.916]
12. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EMM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The Challenges of Primary Biliary Cholangitis: what is new and what needs to be done. J Autoimmun 2019. [Impact factor 12.8; Maximum ranking 0.916]
13. **Terziroli Beretta-Piccoli B**, De Gottardi A, Vergani D, Mieli-Vergani G. Le malattie autoimmuni di fegato nell'adulto, Schweiz. Gastroenterol. <https://doi.org/10.1007/s43472-021-00040-4> Accettato: 26. 4 2021
14. Vergani D, **Terziroli Beretta-Piccoli B**, Mieli-Vergani G. A reasoned approach to the treatment of autoimmune hepatitis. Dig Liver Dis. 2021 Jun 21:S1590-8658(21)00307-8. doi: 10.1016/j.dld.2021.05.033. Epub ahead of print. PMID: 34162505. [Impact factor 4.5; Maximum ranking 0.683]
15. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D. .Autoimmune hepatitis: serum autoantibodies in clinical practice. Clin Rev Allergy Immunol 2021. [Impact factor 9.1; Maximum ranking 0.875]
16. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Cell Mol Immunol. 2021. [Impact factor 24.1; Maximum ranking 0.966]

17. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D. HLA, gut microbiome and hepatic autoimmunity. *Front Immunol* 2022, Aug 18;13:980768. doi.org/10.3389/fimmu.2022.980768. [Impact factor 7.3; Maximum ranking 0.780]

18. Andrade RJ, Aithal GP, de Boer YS, Liberal R, Gerbes A, Regev A, **Terziroli Beretta-Piccoli B**, Schramm C, Kleiner DE, De Martin E, Kullak-Ublick GA, Stirnimann G, Devarbhavi H, Vierling JM, Manns MP, Sebode M, Londoño MC, Avigan M, Robles-Diaz M, García-Cortes M, Atallah E, Heneghan M, Chalasani N, Trivedi PJ, Hayashi PH, Taubert R, Fontana RJ, Weber S, Oo YH, Zen Y, Licata A, Lucena MI, Mieli-Vergani G, Vergani D, Björnsson ES; IAHG and EASL DHILI Consortium. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. *J Hepatol*. 2023 Sep;79(3):853-866. doi: 10.1016/j.jhep.2023.04.033. Epub 2023 May 8. [Impact factor 25.7; Maximum ranking 0.962]

- **Book chapters**

1. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D. Autoantibodies and understanding autoimmune liver disease. In: *Autoimmune Liver Disease*. Hirschfield G, Neuberger J. Eds. Wiley (2019).

2. Vesterhus M, **Terziroli Beretta-Piccoli B**, Muri Boberg K, Mieli-Vergani G. Primary sclerosing cholangitis. In: *Autoimmune Liver Disease*. Hirschfield G, Neuberger J. Eds. Wiley (2019)

3. **Terziroli Beretta-Piccoli B**, Bowls C. Diagnostic Liver Immunology. In: *Liver Immunology*. Gershwin ME, Vierling J, Manns M, Tanaka A. Springer, 3rd Edition 2019.

4. **Terziroli Beretta-Piccoli B**, Vergani D. Adaptive Immunity and the clinical definition of autoantibodies. In: *Liver Immunology*. Gershwin ME, Vierling J, Manns M, Tanaka A. Springer, 3rd Edition 2019.

5. **Terziroli Beretta-Piccoli B**, Selmi C, Manns M, Gershwin ME. Inflammatory hepatobiliary diseases. In: *Clinical Immunology: Principles and Practice*. Robert Rich, 6th Edition 2020

6. **Terziroli Beretta-Piccoli B**, Mieli-Vergani G, Vergani D. Hepatitis. In: Rose Mackay, *The autoimmune diseases*. 7th Edition, in press.

- **Guidelines**

1. Di Donato R, Cerny A, **Terziroli Beretta-Piccoli B**. Expert Opinion Statement of the Swiss Association for the Study of the

Liver. Management of ascites in the cirrhotic patient. Under review

2. Participation in the Delphi process of the "EASL Clinical Practice Guidelines on the Management of Autoimmune Hepatitis" 2024

• Case reports

1. Truttmann AC, **Beretta-Piccoli BC**, Carvajal MI, Bianchetti MG. Arterial hypertension with normal urinalysis in Henoch-Schönlein disease: a further case. *Pediatr Nephrol* 1998; 12: 252. [Impact factor 3; Maximum ranking 0.696]
2. Von Vigier R, Offermann N, **Beretta-Piccoli BC**, Bianchetti MG: Paucisymptomatic hemolytic uremic syndrome. *Pediatr Nephrol* 2000;14: 436-437. [Impact factor 3; Maximum ranking 0.696]
3. Bianchi M, Fornasari D, Antonini RA, **Beretta-Piccoli BC**, Nava S, Neuenschwander H. The pharmacogenetics of morphin-induced analgesia: a case report. *J Pain Symptom Manage* 2008; 36: e10-e12. [Impact factor 4.7; Maximum ranking 0.843]
4. **Terziroli Beretta-Piccoli B**, Mazzucchelli L, Taiana C, Mossi G, Usai C, Vergani D, Mieli-Vergani G. A patient with primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis variant syndrome. *J Transl Autoimmun*. 2019 Dec 17;3:100033. doi: 10.1016/j.jtauto.2019.100033. PMID: 32743518; PMCID: PMC7388380. [Impact factor 3.9; Maximum ranking]

• Abstracts (unpublished data only)

1. **Terziroli Beretta-Piccoli B**, Baserga A, Magenta L, Balmelli M, Moriggia A, Hagara D, Robatto A, Stalder O, Cerny A, De Gottardi A. Treatment cascade of hepatitis C in a non-university hospital setting in Southern Switzerland. Oral presentation SGG-SSG Jahreskongress Interlaken 2018.
2. **Terziroli Beretta-Piccoli B**, Mazzucchelli L, Mossi G, Usai C, Vergani D, Mieli-Vergani G. Coexisting primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis. Poster presentation SGG-SSG Jahreskongress Interlaken 2018.
3. Pareti E, Cioffi G, Cerny A, Stirnimann G, Casu S, Sokollik C, Braegger C, Semela D, Mieli-Vergani G, Vergani D, Mertens J, **Terziroli Beretta-Piccoli B**. Cohort profile: the Swiss Autoimmune hepatitis cohort study. Poster presentation SGG-SSG Jahreskongress Interlaken 2019.
4. Pareti E, Cioffi G, Cerny A, Stirnimann G, Casu S, Baserga A, Semela D, Bellentani S, Filipowicz M, Mertens J, **Terziroli Beretta-**

Piccoli B. Cohort profile: the Swiss Primary Biliary Cholangitis cohort study. Poster presentation SGG-SSG Jahreskongress Interlaken 2019.

5. Baserga A, **Terziroli Beretta-Piccoli B**, Magenta L, Balmelli M, Moriggia A, Hagara D, Robatto A, Stalder O, Appadoo S, De Gottardi A, Cerny A. Treatment cascade of hepatitis C in a non-university hospital setting, that uses a Hub-and-Spoke model, in Southern Switzerland. Poster presentation The International Liver Congress™ 2020, EASL.

6. The Swiss PBC Cohort Study: 5-year report. Oral presentation SGG 2022 Oral presentation SGG-SSG Jahreskongress Interlaken 2018.

- **Editorials**

1. **Terziroli Beretta-Piccoli, B.** and Lleo, A. (2022), Is immunosuppression truly associated with worse outcomes in autoimmune hepatitis patients with COVID-19?. Liver Int, 2022 42: 274-276. <https://doi.org/10.1111/liv.15138>